Figure 6.
Risk stratification in AML according to LSC-17 and ATIC scores. (A) Kaplan-Meier survival curves of patients from the validation cohort according to combined stratification with LSC-17 and ATIC scores (n = 435). (B) Kaplan-Meier survival curves of patients from the HOVON/SAKK cohort (ArrayExpress, E-MTAB-3444) according to combined stratification with LSC-17 and ATIC scores (n = 600). Curve comparison P values are calculated by log-rank test. (C) Annotated heat map showing gene expression and known molecular alterations of patients from the OHSU cohort stratified with LSC-17 and ATIC scores. High and low scores are depicted in red and green, respectively. The presence of molecular alteration is shown by a black bar. Genes used to calculate LSC-17 and ATIC scores are shown in black and red, respectively.

Risk stratification in AML according to LSC-17 and ATIC scores. (A) Kaplan-Meier survival curves of patients from the validation cohort according to combined stratification with LSC-17 and ATIC scores (n = 435). (B) Kaplan-Meier survival curves of patients from the HOVON/SAKK cohort (ArrayExpress, E-MTAB-3444) according to combined stratification with LSC-17 and ATIC scores (n = 600). Curve comparison P values are calculated by log-rank test. (C) Annotated heat map showing gene expression and known molecular alterations of patients from the OHSU cohort stratified with LSC-17 and ATIC scores. High and low scores are depicted in red and green, respectively. The presence of molecular alteration is shown by a black bar. Genes used to calculate LSC-17 and ATIC scores are shown in black and red, respectively.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal